DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
(Thomson Reuters ONE) -
DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in
First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against
Pertussis
DSMB expressed no safety concerns with Viaskin rPT 25 µg
Following positive DSMB review, dosing with Viaskin rPT 50 µg has been initiated
PARIS, BANGKOK and GENEVA November 17, 2016 - DBV Technologies (Euronext: DBV -
ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals
(HUG) and BioNet-Asia Co. Ltd today announced that in a planned interim
assessment of the Phase I trial of Viaskin rPT for booster immunization against
Bordetella pertussis, the independent Data and Safety Monitoring Board (DSMB)
concluded that there were no safety concerns with the administration of Viaskin
rPT 25 mcg in the first subject cohort. Based on this review, enrollment in the
trial has continued as planned, with dosing of Viaskin rPT 50 mcg commencing in
the second subject cohort.
The Viaskin rPT pertussis booster vaccination program intends to test the
ability of DBV's needleless and adjuvant-free patch technology, Viaskin, to
epicutaneously deliver two different doses of BioNet's genetically detoxified,
recombinant pertussis toxin for boosting immunity against whooping cough.
In the first dosing cohort, subjects received two applications of either Viaskin
rPT 25 mcg or placebo. Following the DSMB's positive recommendation, a second
cohort of subjects will receive two applications of Viaskin rPT 50 mcg or
placebo at two-week interval. This Phase I proof of concept study is being
conducted under the supervision of Professor Claire-Anne Siegrist from the
Clinical Research Center of HUG and is sponsored by DBV Technologies.
About the Phase I Viaskin rPT Trial
This Phase I dose-escalation, randomized, double-blind, placebo-controlled
safety and immunogenicity study is assessing the safety of BioNet's genetically-
detoxified recombinant pertussis toxin administered by DBV's Viaskin patches in
60 young healthy adults. Secondary endpoints will assess the patients' humoral
responses elicited by Viaskin rPT 25 mcg and 50 mcg compared to placebo. Immune
cellular responses will also be monitored as exploratory endpoints.
The trial is being conducted in the Clinical Research Center of the Geneva
University Hospitals. Men and women aged 18 to 40 years who have been vaccinated
during childhood against pertussis will be randomized into two cohorts of 30
subjects each. The Viaskin patches will be applied for 48 hours, with a two-week
interval between applications. Four weeks after the second Viaskin application,
participants will receive one dose of Boostrix® dTpa vaccine to ensure the
recall of immunity against diphtheria, tetanus and the three pertussis antigens
(only a single antigen will be delivered through Viaskin rPT). All subjects will
be observed after each application. Local and systemic adverse events will be
monitored.
The first cohort has received two applications of Viaskin rPT 25 mcg or placebo.
Following a positive DSMB review, dosing in the second patient cohort, which is
expected to receive two applications of Viaskin rPT 50 mcg or placebo has
commenced.
About Bordetella Pertussis
Pertussis, commonly known as whooping cough, is a highly contagious respiratory
illness caused by a type of bacteria known as Bordetella pertussis. Pertussis
vaccination is recommended as part of routine childhood immunization. Although
the incidence of pertussis has declined as a result of immunization of infants
and young children, vaccine-induced immunity does not persist for long. This
phenomenon, known as waning immunity, has increased since the introduction of
acellular pertussis vaccines in 1996, which tend to provide short-lived
protection against the Bordetella pertussis bacteria. According to the U.S.
Centers for Disease Control and Prevention (CDC), there are 16 million pertussis
cases worldwide each year, mainly in adolescents and adults who often can infect
infants who have not yet completed their pertussis immunization. In these young
patients, pertussis can be severe and fatal.
Booster immunizations are now recommended for adolescents and adults, but
compliance is not always high. A new vaccine technology that is patient-
friendly, painless and non-invasive could help increase the compliance for
booster immunization against whooping cough.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
About Geneva University Hospitals
The Geneva University Hospitals (HUG), reference academic institution at both
national and international level, gather eight public hospitals of Geneva. Their
centres of excellence cover hepato-biliary and pancreatic diseases,
cardiovascular diseases, oncology, musculoskeletal and sports medicine, old age
medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by
Professor Claire-Anne Siegrist, gained international recognition through the
performance of a large first-in-humans Phase I randomized clinical trial that
enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-
ZEBOV Ebola vaccine candidate.
With their 10,500 employees, the HUG welcome each year 60,000 hospitalized
patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care
and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150
apprentices perform their training here. The HUG are working closely with the
Faculty of Medicine of the University of Geneva and WHO in various training and
research projects. They develop partnerships with CHUV, EPFL, CERN and other
actors from the Lemanic Health Valley. More information on: www.hug-ge.ch
About BioNet-Asia
BioNet-Asia offers access to vaccine and technology through biotech innovation
and partnering networks. BioNet has built several international partnerships
fostering vaccine self-reliance and leading to the supply of billions of doses
of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and
clinical stages. BioNet most advanced program is the development of a new
generation of pertussis vaccines aimed at overcoming the waning immunity
observed with the conventional acellular pertussis vaccines.
BioNet's pertussis vaccines are produced from a new proprietary Bordetella
pertussis strain expressing genetically detoxified Pertussis Toxin (PTgen(TM)).
The unique properties of BioNet's PTgen enables the vaccines to induce superior
anti-PT immune response. For additional information, please visit www.bionet-
asia.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Viaskin as a means of delivering
recombinant pertussis toxin to boost immunity against Bordetella pertussis.
These forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. The Company's product candidates have not
been approved for sale in any jurisdiction. Among the factors that could cause
actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the risk that
historical preclinical results may not be predictive of future clinical trial
results, and the risk that historical clinical trial results may not be
predictive of future trial results. A further list and description of these
risks, uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2015 and
future filings and reports by the Company. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release,
whether as a result of new information, future events or circumstances or
otherwise.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contact
Erinn White, Centron PR
+1-646-722-8822
ewhite(at)centronpr.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
Geneva University Hospitals Contact
Professor Claire-Anne Siegrist, Director of the Center of Vaccinology
+41(22) 379 57 77
claire-anne.siegrist(at)unige.ch
HUG Media Contact
Nicolas de Saussure, PR Officer
+41 (22) 372 60 06
nicolas.desaussure(at)hcuge.ch
BioNet Contact
Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd.
+66 (2) 361 8110
laurent.d(at)bionet-asia.com
PDF Version:
http://hugin.info/156437/R/2057553/770962.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.11.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 507640
Anzahl Zeichen: 11878
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
